Tru Niagen (Nicotinamide Riboside) 300mg

Name: ChromaDex Tru Niagen (Nicotinamide Riboside) 300mg
Brand: ChromaDex
Price: 47.00 USD
Availability: InStock

Solid ChoiceLongevity & Anti-Aging

The most clinically studied NAD+ precursor supplement on the market. ChromaDex's patented Niagen (nicotinamide riboside) has been used in multiple published human trials. 300mg per capsule, FDA safety-notified, and backed by more human data than any competing NAD+ booster.

74/ 100

Biorank Score

Independently ranked

74/ 100

Biorank Score

Independently ranked by Biorank Laboratories

Our Verdict

Solid Choice

Tru Niagen scores 74 — the highest among NAD+ precursors — because it has the strongest human evidence base in this category. ChromaDex has invested heavily in clinical trials and FDA safety notifications (GRAS status). The 300mg dose aligns with the lower end of studied doses. Score remains moderate because even the best NAD+ data shows biomarker changes but not yet proven downstream health outcomes like reduced disease or extended healthspan.

Key Findings

Most clinically studied NAD+ precursor — multiple published human RCTs
Martens et al. (2018) showed NR increased NAD+ metabolome in healthy older adults
Elhassan et al. (2019) demonstrated reduced inflammatory cytokines with NR supplementation
FDA GRAS safety notification — one of the few longevity supplements with this status
Dollerup et al. (2018) found NAD+ increase but no insulin sensitivity improvement — honest mixed results

Evidence Analysis

Nicotinamide riboside (NR) is an NAD+ precursor with the most extensive human clinical trial program of any longevity supplement. Martens et al. (2018, Nature Communications) showed NR supplementation (1000mg/day for 6 weeks) increased NAD+ metabolome and was well-tolerated in healthy middle-aged and older adults. Dollerup et al. (2018, American Journal of Clinical Nutrition) found NR increased NAD+ in obese men but did not improve insulin sensitivity — a more sobering result. Elhassan et al. (2019, Cell Reports) demonstrated NR increased NAD+ and reduced circulating inflammatory cytokines in older adults. ChromaDex holds the patent on Niagen and has funded the majority of NR research, which is both a strength (substantial investment in evidence) and a weakness (funder bias).

Ingredient Breakdown

Ingredient	Dose	Effective Dose	Adequacy	Verdict
Nicotinamide Riboside (Niagen)	300mg	300-1000mg (based on human trials)		Adequate

True Cost Analysis

Properly Dosed -- What You Pay Is What You Get

Listed Price

$1.57/serving

$47.10/month at 1 serving/day

True Cost Per Effective Dose

$1.57/effective dose

$47.10/month for effective dosing

Value Score

Decent value

Save $42.60/month (90%)

by switching to NOW Foods Quercetin 500mg

Where It Falls Short

Most NR research has been funded by ChromaDex, raising legitimate concerns about funder bias. Studies show NAD+ levels increase, but the clinical significance of this biomarker change is not established for longevity outcomes. At $1.57/serving, it is expensive for a supplement without proven long-term health benefits. The 300mg dose is at the lower end of studied doses (most trials used 500-1000mg). ChromaDex has been embroiled in patent litigation with Elysium Health, creating industry drama that has nothing to do with the science.

Best For

People who prioritize clinical evidence and want the most-studied NAD+ precursor
Those who value FDA safety notification (GRAS status) for their supplements
Adults over 50 concerned about age-related NAD+ decline
Consumers who prefer patented, single-ingredient supplements with clear provenance

Not Ideal For

Budget-conscious consumers (NAD+ boosting is an expensive, unproven longevity strategy)
Anyone expecting proven anti-aging effects (NAD+ increase ≠ proven longevity benefit)
Those uncomfortable with most evidence being funder-sponsored
People who need higher doses (300mg is at the low end of studied ranges)